Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a ...

An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

Even worse? It's outfitted with a laughably bad AI-concocted version of the pharmaceutical unicorn Novo Nordisk's logo, complete with incomprehensible gibberish. The company name is clearly ...

Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk is seeking up to US$830 million (S$1.1 billion) in damages from KBP Biosciences, according to a ruling by a ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...